Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD"
Marketwired - Sat Dec 06, 11:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade(R)) and low-dose dexamethasone ("TBorD"
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Marketwired - Tue Nov 25, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a.m. Eastern Time and at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014, at 11:30 a.m. Eastern Time.
THLD: 2.93 (+0.01)
Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 6.99 (-0.03), BCRX: 11.83 (+0.76), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), IDRA: 3.89 (+0.02), QQQ: 104.30 (+0.09), SGEN: 31.10 (-0.14), XBI: 182.62 (+3.44), TGTX: 16.03 (+0.33), IBB: 299.80 (+5.12), THLD: 2.93 (+0.01), IWM: 119.76 (-0.10), TWTR: 37.61 (+0.04), XOMA: 3.68 (+0.11)
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Marketwired - Mon Nov 17, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin(R)) for the treatment of glioblastoma (GBM), the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only U.S. Food and Drug Administration (FDA)-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.
THLD: 2.93 (+0.01)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.49 (+0.29), AGEN: 3.85 (unch), NVAX: 5.81 (+0.18), ALXN: 181.96 (+3.09), PPHM: 1.40 (+0.01), THLD: 2.93 (+0.01), GSK: 42.85 (+0.11), OMER: 22.09 (+0.48)
Alibaba and Ford are big market movers
AP - Tue Nov 11, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 15.30 (-0.03), SFY: 4.47 (-0.06), THLD: 2.93 (+0.01), SFM: 32.70 (+0.02), ZNGA: 2.71 (-0.01), LUV: 41.66 (+0.68), DRI: 58.42 (-0.09), BABA: 105.95 (+0.43)
Threshold Pharma cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:30AM CST
THLD: 2.93 (+0.01)
Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 8.2% (THLD)
Comtex SmarTrend(R) - Tue Nov 11, 10:11AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 8.2% to $3.23 on 1.6x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 756,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
THLD: 2.93 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:17AM CST
JRJC: 5.81 (-0.11), CODI: 15.99 (-0.11), RAX: 48.24 (+0.45), QIWI: 20.88 (+0.36), MCEP: 6.07 (-0.12), PHMD: 1.46 (-0.03), SFM: 32.70 (+0.02), VSLR: 8.97 (+0.18), VOD: 34.65 (-0.05), LITB: 6.30 (+0.10), PT: 1.21 (-0.01), THLD: 2.93 (+0.01), ZNGA: 2.71 (-0.01)
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Marketwired - Tue Nov 11, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Marketwired - Mon Nov 10, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. Eastern Time.
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Marketwired - Thu Nov 06, 8:06AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade(R)) in patients with relapsed/refractory multiple myeloma will be presented in a poster at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco, California, from December 6 - 9, 2014 (Abstract #2142).
THLD: 2.93 (+0.01)
Threshold Pharma ups revenues 16% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:43AM CST
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals posts 3Q loss
Automated Insights - Mon Nov 03, 6:06AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Monday reported a third-quarter loss of $7.7 million.
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:05AM CST
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Marketwired - Mon Nov 03, 6:05AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin(R) (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) held in Miami, Florida, from November 13-16, 2014.
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Marketwired - Mon Nov 03, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September 30, 2014 was $7.6 million. The net loss for the third quarter ended September 30, 2014 was $7.7 million, which included the operating loss of $7.6 million and non-cash expense of $0.3 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2014, Threshold had $68.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.93 (+0.01)
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Marketwired - Mon Nov 03, 5:59AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold has a global license and co-development agreement with Merck KGaA, Darmstadt, Germany for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
THLD: 2.93 (+0.01)
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 10.91 (+0.36), PGNX: 6.99 (-0.03), IDRA: 3.89 (+0.02), THLD: 2.93 (+0.01), FOLD: 7.94 (+0.06)